Status:

COMPLETED

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Cushing's Syndrome

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's...

Eligibility Criteria

Inclusion

  • Patients with pituitary Cushing's disease within the two months prior to study entry
  • Patients for whom written informed consent to participate in the study has been obtained
  • Female patients of child bearing potential who have not undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation must agree to use barrier contraception throughout the course of the study, and for one month after the study has ended

Exclusion

  • Female patients who are pregnant or lactating
  • Patients who have been previously treated with certain medications may be required to be without certain medications prior to entering the study
  • Poorly controlled diabetes mellitus as indicated by the presence of ketoacidosis or HgbA1C \> 10
  • Patients who have congestive heart failure, unstable angina, cardiac arrhythmia or history of acute MI less than one year prior to the study entry or clinically significant impairment in cardiovascular function (e.g. blood pressure of 190/100mmHg or greater)
  • Patients with chronic liver disease
  • Patients with clotting disorders or abnormal blood counts
  • History of immuno-compromise, including a positive HIV test result
  • Patients with active gall bladder disease
  • Patients who have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
  • Patients with active malignant disease (with the exception of basal cell carcinoma or carcinoma in situ of the cervix)

Key Trial Info

Start Date :

April 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT00088608

Start Date

April 1 2004

Last Update

November 7 2016

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Cedars-Sinai Pituitary Center

Los Angeles, California, United States, 90048

2

Massachusetts General Hospital NE Unit

Boston, Massachusetts, United States, 02114

3

Oregon Health & Science University

Portland, Oregon, United States, 97239

4

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104